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The Hedgehog (Hh) signaling pathway is a develop-
mentally conserved regulator of stem cell function.
Several reports suggested that Hh signaling is an
important regulator of hematopoietic stem cell
(HSC) maintenance and differentiation. Here we test
this hypothesis in vivo using both gain- and loss-of-
function Hh genetic models. Surprisingly, our studies
demonstrate that conditional Smoothened (Smo)
deletion or overactivation has no significant effects
on adult HSC self-renewal and function. Moreover,
they indicate a lack of synergism between the Notch
and Hh pathways in HSC function, as compound
RBPJ and Smo deficiency does not affect hemato-
poiesis. In agreement with this notion, detailed
genome-wide transcriptome analysis reveals that
silencing of Hh signaling does not significantly alter
the HSC-specific gene expression ‘‘signature.’’ Our
studies demonstrate that the Hh signaling pathway
is dispensable for adult HSC function and suggest
that Hh inhibition on leukemia-initiating cell mainte-
nance can be targeted in future clinical trials.
INTRODUCTION
Hematopoietic stem cells (HSCs) are able to self-renew as well
as give rise to all blood lineages. HSCs mainly reside in special-
ized bone marrow microenvironments, called HSC niches. The
niche is thought to provide appropriate signals that maintain
the balance between self-renewal and differentiation of HSCs
(Adams and Scadden, 2006; Lessard et al., 2004; Moore and
Lemischka, 2006; Morrison and Spradling, 2008; Wilson and
Trumpp, 2006; Yin and Li, 2006). However, the identity of these
signals and the molecular mechanisms governing HSC fate
largely remain elusive. Thus, identification of regulators of HSC
function is a central issue in stem cell biology.548 Cell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc.The roles of developmentally imprinted signaling pathways—
more specifically Notch, Wingless (Wnt), and Hedgehog (Hh)—
in HSC homeostasis have been studied extensively (Maillard
et al., 2008; Stier et al., 2002; Cobas et al., 2004; Reya et al.,
2003). Hh is a secreted protein familywith three members in higher
vertebrates (Shh, Ihh, Dhh). In the absence of Hh, the Patched
(Ptch) receptor acts as a negative regulator of signaling as it
inhibits the action of Smoothened (Smo) (Hammerschmidt et al.,
1997). Hh protein binds and inhibits Ptch action, inducing
signaling transduction through Smo. This signaling cascade
results in the nuclear localization and activation of the Gli family
of transcription factors. Although Hh is a major regulator of cell-
fate decision and body segment polarity (Nusslein-Volhard and
Wieschaus, 1980), its role in HSC homeostasis and differentiation
remains controversial. Several reports have suggested that Hh
signaling is critical for HSCand hematopoietic progenitor differen-
tiation. A study of zebrafish hematopoiesis revealed that embryo
mutants of the Hh pathway display defects in HSC formation (Ger-
ing and Patient, 2005), indicating that Hh is required for definitive
hematopoiesis. Consistent with these data, in vitro studies found
that antibodies to Hh inhibited the cytokine-induced proliferation
of human primitive HSCs, whereas Shh induced the expansion of
human hematopoietic repopulating cells (Bhardwaj et al., 2001). In
addition, analysis of Ptch1+/ mice showed that Hh activation
expanded primitive bone marrow cells, but continued Hh activa-
tion led to HSC exhaustion (Trowbridge et al., 2006). Furthermore,
a recent study using an in vivo model of Hh deficiency suggested
that HSCs require Smo-mediated signals for their homeostasis
(Zhao et al., 2009). In contrast to these studies, it was proposed
that Hh signaling is involved at the level of lymphocyte lineage
commitment, as a defect in the common lymphoid progenitor
(CLP) population was observed upon deletion of Ptch1 (Uhmann
et al., 2007). Moreover, Hh signaling has been demonstrated to
be important for the differentiation and proliferation of hematopoi-
etic progenitors in the thymus (Crompton et al., 2007; El Anda-
loussi et al., 2006). Finally, a recent report suggested that Hh
signaling is essential for the differentiation of leukemia-initiating
cells, introducing Hh inhibitors in clinical trials targeting BCR-
ABL+ leukemia (Dierks et al., 2007, 2008).
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cally in adult HSCs, we decided to address HSC-specific Hh
function in vivo. To this end, both gain- and loss-of-function
conditional Smo genetic models were used, as the Smo receptor
is the only nonredundant element of the Hh pathway. Surpris-
ingly, and contrary to the consensus view, Hh signaling appeared
to be dispensable for the self-renewal and differentiation of adult
bone marrow HSCs. Indeed, neither conditional deletion of the
Smo signal transducer nor hyperactivation of the Hh pathway
had an affect in adult HSC maintenance and function. Interest-
ingly, Hh signaling also appeared to be dispensable for the func-
tion of putative leukemia-initiating cells in T cell leukemia, as
induction and progression of the disease was unaffected by
silencing of the pathway.
RESULTS
Conditional Deletion of Smo Fails
to Affect HSC Maintenance In Vivo
To study the role of Hh signaling in adult HSCs, we generated
a Cre-regulated conditional model of Smo deletion (SmoF/F
Mx1-Cre+, Figure 1A) in which expression of the Cre recombi-
nase is under the control of myxovirus-resistance 1 (Mx1) gene
promoter (Mx1-Cre) (Gu et al., 1994) and is induced by inter-
feron-a (via stimulation with polyI:polyC). In these mice, the first
exon of the Smo locus is flanked by loxP sites and is deleted
upon Cre-mediated recombination (Long et al., 2001). SmoF/F
Mx1-Cre (control) and SmoF/FMx1-Cre+ littermate mice were
treated with polyI:polyC. This treatment resulted in the efficient
deletion of Smo floxed alleles, and the generation of a recom-
bined Smo deleted (D) alleles (Figure 1B, lane 4). At the mRNA
level, Smo was not detectable in SmoD/D bone marrow cells,
and the expression of Ptch1, a key target gene of Hh activation,
was significantly reduced compared to the control mice
(Figure 1C).
Initial analysis of control and Smo-deficient mice at 4 weeks
post-polyI:polyC injection demonstrated no significant alteration
in the overall bone marrow cellularity (p = 0.10). Further analysis
showed that Smo deletion had no effect on the relative frequency
(p = 0.35) or the absolute number of LinSca1+cKit+ (LSK), a
cell population enriched for HSCs (p = 0.49) (Figure 1D). HSCs
differentiate and give rise to myeloid progenitors (MP, Lin
Sca1cKit+), which can be subdivided into common myeloid
progenitors (CMP, LinSca1cKit+CD34+FcgRlow), granulocyte-
monocyte progenitors (GMP, LinSca1cKit+ CD34+FcgRhi),
and megakaryocyte/erythrocyte progenitors (MEP, LinSca1
cKit+CD34FcgRlow). Our analysis showed that CMP, GMP,
and MEP compartments were comparable between Smo-defi-
cient and control mice (Figure 1E). Moreover, the percentages
of terminally differentiated B- and T-lymphocytes appear normal
in Smo-deficient spleen and bone marrow (see Figure S1 avail-
able online). In the thymus, the distribution of mature (CD4+,
CD8+) and immature (CD4+8+, CD48) compartments appeared
similar to controls. Further subdivision of the CD48 compart-
ment using the CD25 and CD44 surface antigen expression
also revealed a normal distribution (Figure S1). The lack of
a perturbation of the hematopoietic compartment was not due
to early time point analysis, as Smo-deficient mice at 16 weeks
post-polyI:polyC injection also displayed normal populations ofLSK, progenitors, and lymphocytes despite the complete
absence of Smo mRNA (Figure S2).
We further examined the LSK population, which can be subdi-
vided into long-term (LT)-HSC (LSKCD34Flt3/Flk2), short-
term (ST)-HSC (LSKCD34+Flt3/Flk2), and multipotent progeni-
tors (MPP, LSKCD34+Flt3/Flk2+). We observed comparable
numbers of LT-HSCs, ST-HSCs, and MPPs between control
and Smo-deficient mice (Figure 1E). Also, similar analysis using
CD150 and CD48 as markers of LT-HSC (LSKCD48CD150+)
did not reveal any abnormalities in Smo-deficient mice
(Figure 1E). Additionally, we investigated the prosurvival and pro-
proliferative functions of the Hh pathway. Staining for the proa-
poptotic marker AnnexinV did not reveal abnormal induction of
cell death in Smo-deficient LSKs. Furthermore, cell-cycle anal-
ysis of the marker for proliferation Ki67 in conjunction with
DAPI to measure DNA content did not reveal any differences in
the cell-cycle profiles between control and Smo-deficient LSKs
(Figure 1E). These findings strongly suggested that Smo-medi-
ated Hh signaling is dispensable for adult HSC and progenitor
homeostasis and differentiation. To further test this hypothesis,
we analyzed Gli1lacZ/lacZ mice (Bai et al., 2002) in which Gli1,
a key transcription activator of the Hh pathway, is deleted and
replaced by a lacZ allele. We did not detect any defects in the
HSC compartment or in T and B lymphopoiesis in the bone
marrow and the thymus ofGli1lacZ/lacZ mice (Figure S3), suggest-
ing that Gli1 function is dispensable for hematopoiesis.
Smo Deletion Does Not Alter Differentiation Ability
of Progenitor Cells
To test functionality of Smo-deficient stem cells and progenitors,
LSKs were flow purified from either control or Smo-deficient
bone marrows, and methylcellulose assays were performed in
the presence of the appropriate cytokines. Both types of LSK
cells generated similar numbers of colony-forming units (CFUs)
in both primary and secondary platings (Figures 2A and 2B).
The deletion of Smo was confirmed by colony-specific PCR.
The results showed that 14 out of the 15 studied colonies derived
from Smo-deficient LSKs deleted the Smo allele. The expression
ofSmomRNA was not detectable by quantitative RT-PCR; more-
over, the expression of Ptch1 mRNA was significantly reduced in
Smo-deficient LSK-derived colonies (Figures 2C and 2D). These
results suggest that Smo is dispensable for short-term differenti-
ation ability of hematopoietic progenitor cells.
ST-HSCcellsare able togive rise rapidly tocolonies in thespleen
when transplanted into lethally irradiated hosts. To study the effect
of Smo deletion in this process, CFU-spleen (CFU-S) units were
scored after transplanting either control or Smo-deficient bone
marrow cells. We obtained identical CFU-S scores for the two
groups (Figure S4), again indicating that Smo function is dispens-
able for rapid progenitor differentiation. To test the capability of
Smo-deficient progenitors to expand and replenish the immune
system, control and Smo-deficient mice were challenged weekly
with a dose of 5-fluorouracil (5-FU) to eradicate cycling cells
(Berardi et al., 1995), and the survival of these mice was observed.
Similar survival percentages in the two groups (Figure 2E) sug-
gested that the Smo-deficient progenitor cells were able to enter
into cell cycle at a comparable level as wild-type cells. Collectively,
these results demonstrate that Smo is dispensable for short-term
differentiation of adult progenitor cells both in vitro and in vivo.Cell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc. 549
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Figure 1. Phenotypically Normal HSCs and Progenitors in Smo-Deficient Mice
(A) Schematic representation of Smo-floxed allele (upper lane) and Mx1-Cre allele (lower lane).
(B) PCR of genomic DNA extracted from mouse tails or lineage-negative bone marrow cells to detect the Smo floxed, deleted (D), or Cre allele. Lanes 1 and 3,
SmoF/FMx1-Cre; lanes 2 and 4, SmoF/FMx1-Cre+.
(C) RT-PCR and quantification of Smo and Ptch1 mRNA in lineage-negative bone marrow cells from polyI:polyC-injected SmoF/FMx1-Cre (lane 5) and SmoF/F
Mx1-Cre+ (lane 6) mice. The expression levels were normalized against b-actin.
(D) Total number of bone marrow cells and LSK cells in control and SmoD/D mice. Each diamond represents a single mouse, and the bar indicates the average
numbers.
(E) FACS plots of bone marrow from control and SmoD/D mice. Representative plots (from at least 20 individual experiments) are shown.Smo Deletion Does Not Affect HSC Self-Renewal
and Reconstitution Ability
One explanation for the lack of an overt effect of Smo loss on
HSC maintenance or function is that the potential Hh function
is masked due to the nature of the analysis utilized and that it
can be revealed only in a competitive setting. To test the recon-
stitution capacity of Smo-deficient HSCs, competitive bone
marrow transplantations (BMTs) were performed. Bone marrow
cells from either control or Smo-deficient mice (CD45.2+/Ly5.2+)
were competed with an equal number of bone marrow cells from
isogenic CD45.1+/Ly5.1+ mice and transplanted into lethally irra-
diated Ly5.1+ recipients (Figure 3A). Peripheral blood analysis of
chimerism of the recipients showed that Smo-deficient HSCs
were able to compete with wild-type HSCs in a manner similar
to control HSCs (Figure 3B). Similar assays were performed by
mixing flow-purified LSKs from either control or Smo-deficient
mice with competing Ly5.1 bone marrow cells. Once more, no
significant differences were observed between control and550 Cell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc.Smo-deficient LSKs 14 weeks after BMT (Figure 3C). This lack
of phenotype was not due to partial or inefficient deletion of
the Smo, as quantitative RT-PCR in flow-purified Ly5.2+Lin
bone marrow cells of recipient mice 16 weeks after BMT showed
a complete loss of SmomRNA expression (Figure 3D). Indeed, at
week 16 after BMT, Ly5.2+ Smo-deficient donor-cell-derived
LSK cells were present in the bone marrow, B220+ B cells, and
CD3+ T cells in the spleen of recipients (Figure 3E), demon-
strating the repopulation ability of Smo-deficient HSCs.
To more rigorously test the repopulation ability of Smo-defi-
cient HSCs, a secondary competitive BMT was performed using
donor-derived Ly5.2+ bone marrow cells isolated from the recip-
ients of the primary transplant. We observed that the reconstitu-
tion ability of Smo-deficient HSCs was identical to that of control
HSCs even in this sensitive serial transplantation setting. As
shown in Figure 3F, at 12 weeks postsecondary BMT, the chime-
rism in peripheral blood was comparable between recipients that
had received control or Smo-deficient cells, and donor-derived
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Figure 2. Physiological Differentiation of Smo-Deficient Progenitors
(A) The number of colonies was scored on day 7 of methylcellulose assay, and images of plates are shown on right panel.
(B) The number of colonies was scored on day 7 after replating cells from (A).
(C) PCR on genomic DNA of colonies formed from (A). The Smo D allele and a loading control genomic allele are shown.
(D) Quantitative RT-PCR of Smo and Ptch1 on colonies formed from (A). The expression levels were normalized against b-actin.
(E) Survival curve of control (gray) or SmoD/D (black) mice after weekly 5-FU injection (n = 5).B220+, CD3+, and Mac1+ cells were present at similar percent-
ages. Taken together, these data indicate that deletion of Smo
has no significant effect on HSC repopulation ability.
Smo Deletion Does Not Alter HSC-Specific Gene
Expression Signature
The absence of a phenotypic defect in HSCs that lackSmo led us
to search for a putative role for Hh signaling in stem cell and
progenitor gene expression patterns. To examine whether the
loss of Smo results in changes at the molecular level in HSCs, mi-
croarray analysis was performed using flow-purified LSK and MP
populations from either control or Smo-deficient mice. The array
analysis (Figure S5C) and qRT-PCR studies (data not shown)
showed a complete loss of Smo expression in both LSK and
MP compartments. When control LSKs were compared with
control MPs in duplicate experiments, 739 genes changed
expression levels by 2-fold or greater (Figure S5A). For the
purpose of this analysis, these 739 genes were regarded as an
HSC-enriched gene expression ‘‘signature.’’ As a proof of prin-
cipal, it was shown that this specific gene ‘‘signature’’ was lost
upon deletion of Fbw7, a ubiquitin ligase that is essential for the
maintenanceof HSC quiescence (Thompson et al., 2008). Indeed,
43% (315 out of 739) of these selected genes were significantly
deregulated in Fbw7-deficient LSKs. In contrast, less than 10%
(70 out 739) of these genes changed (up- or downregulated) in
response to Smo deletion (Figure S5B), suggesting that the
HSC gene signature is largely preserved in Smo-deficient LSKs.
Previous reports (Forsberg et al., 2005; Jankovic et al., 2007;
Mansson et al., 2007; Terskikh et al., 2003; Thompson et al.,
2008) have defined a list of genes closely associated with
LT-HSC activity. These genes are highly expressed in LT-HSCs
but are downregulated as HSCs lose their self-renewal abilities.
These genes include transcription factors/cofactors important
for HSC self-renewal and differentiation (Meis1, Egr1, Eya1/2),
surface receptors (Mpl, Thy1, Agpt), and regulators of HSC
survival (Mcl1). Our array analyses showed that the expression
of these genes was not altered by the inducible deletion ofSmo (Figure S5C). These data demonstrate that Smo is not
required for the maintenance of adult HSC properties at the
molecular level and support our findings that HSCs are pheno-
typically normal in the absence of Smo.
Absence of Functional Redundancy between
the Notch and Hh Pathways in Hematopoiesis
The possibility remains that redundancy between signaling path-
ways masked a potential function for Hh in the early stages of
hematopoiesis. We have shown previously that the Hh and
Notch pathways share similar expression patterns and putative
functions. Also, Smo mRNA expression appears to be signifi-
cantly induced in response to Notch activation in Linneg bone
marrow progenitors (El Andaloussi et al., 2006; Vilimas et al.,
2007). These observations suggest a functional redundancy
between the two pathways in adult HSC function. To test this
hypothesis, we generated mice deficient for both Smo and
RBPJ, a DNA-binding factor required for canonical Notch
signaling, and performed competitive BMT. We injected polyI:
polyC into RBPJF/FSmoF/FMx1-Cre+ mice and confirmed the
excision of Smo- and RBPJ-floxed alleles as well as the recom-
bination of both alleles in the bone marrow (Figure 4A). Next we
performed competitive BMT and found thatRBPJ/Smo-deficient
(DKO) cells were able to efficiently reconstitute irradiated hosts.
Analysis of chimerism in the peripheral blood 6–10 weeks after
BMT did not reveal any defects for DKO cells (Figure 4B). In
fact, donor cells derived from DKO bone marrow were able to
give rise to LSKs in bone marrow (Figure 4C) and B220+ cells
in the spleen (Figure 4F). There were no significant differences
in the number of donor-derived LSKs between the two groups
12 weeks post-BMT (Figure 4D). As expected, donor-derived
T cells (CD4+CD8+ T cells in thymus, and TCRb+ cells in spleen)
(Figures 4E and 4F) and marginal zone B cells (B220+CD21high
CD23low/ cells in spleen) (Figure 4F) were reduced in recipients
transplanted with DKO bone marrow, since Notch signaling is
required for the development of these two lineages. Collectively,
these results show that neither Notch nor Hh signaling isCell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc. 551
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Figure 3. Physiological Competitive Ability of Smo-Deficient Hematopoietic Progenitors
(A) Scheme of primary and secondary BMT.
(B) Percentage of chimerism in peripheral blood of recipient mice at different time points after primary competition BMT. Donor cells were total bone marrow cells.
Mean ± SD are shown (n = 8).
(C) Chimerism of peripheral blood of recipient mice 14 weeks after primary competition BMT. Donor cells were flow-purified LSK cells. Mean ± SD are shown
(n = 4).
(D) Quantitative RT-PCR of Smo in flow-purified Ly5.2+Lin bone marrow of recipients 16 weeks after BMT. Grey, control; black, SmoD/D. The expression levels
were normalized against b-actin.
(E) Representative FACS plot of bone marrow and spleen of primary recipient mice 16 weeks after BMT.
(F) Representative FACS plot of peripheral blood in the recipient (n = 4 for each genotype) 12 weeks after secondary competition BMT.necessary for adult HSC maintenance and differentiation.
Furthermore, these data suggest that these two pathways are
not redundant in governing HSC fate.
Mapping of Hh Signaling Component Expression
in HSCs and Their Niche
The absence of a phenotype in Smo-deficient HSCs suggested
that the Hh signaling might not be active or of low activity in these
cells. To determine whether elements of the Hh signaling
network can be detected in either HSCs or the HSC ‘‘niche,’’
the expression of the components of this pathway was examined
in flow-purified LSKs and differentiated MPs. We found that both
the Smo transducer and Ptch1 receptor mRNAs (which is also
a target gene of Hh signaling) were expressed in LSKs and
MPs (Figure S6A). In contrast, the members of Hh ligand family,
Ihh and Dhh, but not the Shh mRNA, were detected in primary
preparations of calvarial osteoblasts, cells that comprise the
osteoblastic HSC niche (Figure S6B), demonstrating that Hh
ligands are available to HSCs. Several mouse and human oste-552 Cell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc.oblastic lines showed similar Hh expression profiles (data not
shown). However, the expression of the downstream transcrip-
tion factors Gli1, Gli2, and Gli3 was not detectable in either
LSKs or MPs by quantitative PCR (Figure S6C) and microarray
analysis (data not shown), a result that suggested low levels of
Hh activity in both LSK and MP populations. Therefore, these
data indicate that HSCs and progenitors have the ability to
receive Hh signaling, since they express both the Smo and
Ptch1 receptors and Hh ligands are present in the niche. Never-
theless, there is little ongoing Hh activity as the transcription
factors are not expressed, which is consistent with the described
lack of HSC phenotype in Smo-deficient mice.
Hh Pathway Activation Does Not Expand HSCs
or Enhance Their Engrafting Ability
It has been proposed previously that Hh morphogens could be
used for in vitro expansion of primitive stem cell and progenitor
populations and thus could be beneficial in transplantation
protocols (Bhardwaj et al., 2001). Our results have shown an
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Figure 4. Physiological Competitive Ability of RBPJ and Smo Double-Deficient Progenitors
(A) PCR of genomic DNA extracted from bone marrow cells of polyI:polyC-injected RBPJF/FSmoF/FMx1-Cre mice (control) and RBPJF/FSmoF/FMx1-Cre+ mice
(DKO). Smo and RBPJ floxed and deleted (D) alleles were detected.
(B) Chimerism of total peripheral blood (upper panel) or Mac1+Gr1+ cells in peripheral blood (lower panel) of recipient mice at different time points after primary
competition BMT. Donor cells were mixed of 1:2 ratios of Ly5.1+ cells and Ly5.2+ cells. Ly5.2+ cells were either from control (gray) or DKO mice (black). Mean ± SD
are shown (n = 2 for control, n = 6 for DKO).
(C) Representative FACS plot of bone marrow in the recipient mice 12 weeks after competitive BMT.
(D) Number of donor-derived LSK cells in bone marrow 12 weeks after BMT. Mean ± SD are shown (n = 10 for control, n = 4 for DKO).
(E) Representative FACS plot of thymus in the recipient at 12 weeks after competition BMT.
(F) Representative FACS plot of spleen in the recipient 12 weeks after competitive BMT.incomplete Hh activation in HSCs, suggesting that Hh pathway
activation could either expand HSCs or provide them with
competitive advantage in transplantation settings. To directly
test this hypothesis, we used a Hh gain-of-function model
(R26SmoM2) in which enhanced yellow fluorescent protein
(EYFP) was fused with the constitutively active W539L point
mutation of the mouse smoothened homolog gene (SmoW539L)
and ‘‘knocked’’ into the ubiquitously expressed ROSA26 locus
(Jeong et al., 2004). The expression of SmoM2/EYFP fusion
gene is blocked by a loxP-flanked STOP fragment inserted
between the ROSA26 promoter and the SmoW539L/EYFP
sequence (Figure 5A). We crossed these mice to the Mx1-Cre
stain and generated R26SmoM2/SmoM2Mx1-Cre+ (referred to here-
after as Cre+) or R26SmoM2/SmoM2 Mx1-Cre (referred to as Cre)
and induced SmoW539L/EYFP expression by injecting polyI:po-
lyC. As shown in Figure 5B, YFP expression was detected by
flow cytometry in LSKs of Cre+ mice after polyI:polyC adminis-
tration. At the mRNA level, both Smo and Ptch1 expression
were significantly increased in the LSKs of Cre+ compared toCre mice (Figure 5C), demonstrating the overexpression of
Smo and activation of the Hh pathway. Also, it was found that
elements of the Hh pathway (Ptch, Gli1) were aberrantly ex-
pressed in differentiated hematopoietic cells (thymic CD4+8+
cells) in which the pathway is normally silent (data not shown).
An additional indication of nonphysiological Hh activation was
that the majority of Cre+ mice died later in life due to the develop-
ment of tumors (primarily medulloblastomas and skin tumors,
data not shown). However, Cre+ mice did not show any increase
in absolute numbers of LSKs (Figure 5D), illustrating that the
hyperactivation of Hh signaling was unable to result in expansion
of the LSK compartment. Moreover, LSKs of Cre+ mice did not
show any signs of enhanced (or suppressed) apoptosis or aber-
rant cell-cycle profiles, as shown by AnnexinV or Ki67 staining.
Finally, no major defects in lymphopoiesis were detected
(Figure 5E).
To further examine whether hyperactivation of Hh influences
the ability of LSKs to differentiate, CFU methylcellulose-based
assays were performed. We observed that Smo mutant LSKsCell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc. 553
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Figure 5. Hyperactivation of the Hh Pathway Does Not Expand HSC Compartment
(A) Schematic representation of R26SmoM2 locus (upper panel) and Mx1-Cre locus (lower panel).
(B) Histogram of YFP gated on LSKs. Grey line, Rosa26SmoM2/SmoM2Mx1-Cre; black line, R26SmoM2/SmoM2Mx1-Cre+.
(C) Quantative RT-PCR of Smo and Ptch1 in LSKs. The expression levels were normalized against b-actin.
(D) Frequency of LSK cells. Each diamond represents a single mouse, and the bar indicates the average number.
(E) Representative FACS plots of bone marrow from R26SmoM2/SmoM2Mx1-Cre and R26SmoM2/SmoM2Mx1-Cre+ mice.
(F) Number of colonies was scored on first and secondary plating of methylcellulose assay.
(G) Histogram of YFP gated on lineage-negative cells of bone marrow, which were used for BMT in (H). Grey line, Rosa26SmoM2/SmoM2Mx1-Cre; black line,
R26SmoM2/SmoM2Mx1-Cre+.
(H) Percentage of peripheral blood chimerism in recipient mice after competitive BMT of R26SmoM2/SmoM2Mx1-Cre (gray) and R26SmoM2/SmoM2Mx1-Cre+ (black)
at different time points. One line represents one mouse (n = 4).gave rise to similar number of colonies as controls. Moreover, re-
plating of the colonies that originated from the Hh hyperactive
LSKs also generated an identical number of colonies as controls
(Figure 5F).
To directly test the reconstitution ability of Hh hyperactive
HSCs, we transplanted bone marrow cells from polyI:polyC-
treated Cre+ mice (Ly5.2+) mixed with Ly5.1+ competing bone
marrow into lethally irradiated Ly5.1+ hosts. Bone marrow cells
used for competitive BMT were confirmed to express YFP as
shown in Figure 5G. The chimerism in the peripheral blood
4–12 weeks after transplant was similar between Cre and
Cre+ groups (Figure 5H), indicating that overexpression of an
activated Smo does not provide a competitive advantage to
HSCs. These observations argued against the suggestion that
Hh hyperactivation affects HSC expansion and in vivo fitness.554 Cell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc.Hedgehog Signaling Is Dispensable for the Induction
or Maintenance of Lymphoblastic Leukemia
Our studies so far do not support a role for Hh signaling in phys-
iological adult HSC function. Recent reports (Dierks et al., 2008;
Zhao et al., 2009) suggested that Hh could affect BCR-ABL+
leukemia stem cell function and disease progression. These
conclusions led us to study the potential role of Hh in the induc-
tion and maintenance of a different leukemia type, acute lympho-
blastic leukemia (ALL). It has been shown that the majority of
primary cases of T cell ALL (T-ALL) carry activating NOTCH1
mutated alleles (Weng et al., 2004). The study of these tumors
has revealed that the Hh pathway was active in T-ALL, since
both GLI1 and PTCH1 were highly expressed in many Notch1
mutant T-ALL cell lines (J.G., unpublished data) and PTCH1
were expressed in majority (38 out of 48) of primary T-ALL cases
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Figure 6. Leukemia (T-ALL) Induction and Maintenance Is Not Altered by Smo Deficiency
(A) RT-PCR of PTCH1 in primary T-ALL samples. GAPDH served as a loading control.
(B) Representative FACS plots for CD4 and CD8 staining of peripheral blood from the recipients 2 weeks following transplantation with Notch-IC-infected control
or SmoD/D lineage-negative bone marrow cells. Notch-IC-infected cells were identified by gating on GFP+ cells.
(C) Survival curve of host mice transplanted with Notch-IC-infected control (black) or SmoD/D lineage-negative bone marrow cells (gray) (n = 5).
(D) PCR of Smo-floxed and D alleles on genomic DNA purified from GFP+CD4+CD8+ peripheral blood of host mice in (B).
(E) Representative FACS plots for CD4 and CD8 staining of peripheral blood from the recipients (n = 5) 3 weeks after secondary BMT. GFP+ (53 106) bone marrow
cells from primary recipients were used for secondary BMT.(Figure 6A). Thus, to test whether Hh signaling is required for the
transformation of hematopoietic progenitors in T-ALL, a well-
characterized transplantation model (Vilimas et al., 2007) was
used. Lineage-depleted bone marrow from either polyI:polyC-in-
jected SmoF/FMx1-Cre or SmoF/FMx1-Cre+ mice was isolated
and infected with a bicistronic retroviral vector expressing the
intracellular domain of Notch1 (Notch-IC), and green fluorescent
protein (GFP). As expected, peripheral blood analysis of recipi-
ents of Notch-IC-infected control cells revealed that the majority
of cells were GFP+, a marker of Notch-IC expression, most of
which were CD4+8+, a manifestation of T-ALL (Figure 6B). Exam-
ination of recipients that had received Notch-IC-infected Smo-
deficient cells showed similar percentages of GFP+CD4+CD8+
cells in the peripheral blood as well as kinetics of leukemogen-
esis (Figures 6B and 6C). We further confirmed that T-ALL cells
developed from Smo-deficient progenitors deleted the Smo-
floxed and harbored a SmoD allele (Figure 6D), which demon-
strated that Hh signaling is dispensable for T-ALL generation.
To address the ability of Smo-deficient tumors to regenerate,
we performed secondary BMTs using Notch1-transformed
(GFP+) leukemic cells. No significant differences in the induction
of secondary leukemia were noted, in opposition to a role for Hh
signaling in the regulation of putative ‘‘leukemia-initiating’’ cells
(Figure 6E). To further demonstrate that Hh signaling is not
essential for the maintenance of the transformed cells, several
T-ALL lines (PTCH1 and GLI1 positive) were incubated with the
potent and specific Smo inhibitor cyclopamine. In agreement
with our in vivo data, the presence of cyclopamine did not affect
the leukemic cell line survival or the rate of proliferation (data notshown). Taken together, these results indicate that Hh activation
is dispensable for the transformation of hematopoietic progeni-
tors and the progression of Notch-induced T-ALL.
DISCUSSION
In this study, we demonstrate that inducible genetic deletion of
the only nonredundant element of the Hh cascade, Smo, was
unable to affect adult hematopoiesis, specifically at the level of
the HSC. Smo-deficient HSCs display normal abilities to differ-
entiate, self-renew, and regenerate the immune system. In
agreement with these phenotypic and functional studies, gene
expression profiling analysis demonstrated that HSC-specific
gene expression ‘‘signature’’ was preserved in Smo-deficient
HSCs. Interestingly, the simultaneous ablation of both the Hh
and Notch pathways was also unable to affect HSC differentia-
tion and function. Moreover, using a gain-of-function model,
we found that Hh hyperactivation did not lead to expansion of
the HSC compartment. Finally, Smo deletion had no effect on
the ability of the Notch1 oncogene to transform early HSCs
and progenitors and to induce T-ALL. All of these findings are
of unique importance, as they directly question the current
consensus on the role of Hh signaling in adult hematopoiesis.
Our studies are in contrast to a recent report by Zhao et al. that
also used a conditional Smo allele deletion (Zhao et al., 2009).
One possible explanation for this discrepancy is the utilization
of a distinct mode of deletion. Zhao et al. use the Vav-cre deleter
strain that appears to be hematopoietic specific; however, it is
able to delete the Smo alleles in both adult and fetalCell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc. 555
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promoter can efficiently drive Cre-recombinase expression in
E13.5 fetal liver HSC (Stadtfeld and Graf, 2005). It is possible
that the reported HSC defects in the Vav-creSmoF/F model reflect
Hh signaling functioning not in adult but in fetal HSC function and
hematopoiesis. Although future work is required to identify puta-
tive Hh roles in fetal hematopoiesis, our data clearly demonstrate
that Hh signaling is dispensable for adult HSC function.
Our observations suggest that Hh hyperactivation is unable to
expand bone marrow stem cells and progenitors, a conclusion
that is inconsistent with a report by Trowbridge and colleagues
(Trowbridge et al., 2006). A potential reason for this discrepancy
could be the utilization of different animal models. In the germline
Ptch+/ model, HSC and/or the HSC ‘‘niche’’ could contribute to
phenotype, whereas in the inducible SmoM2 model, expression
of the activated allele is largely restricted to the hematopoietic
compartment. Moreover, putative differences on the effect of
Hh hyperactivation on HSC/LSK cell-cycle progression could
be explained by the differential analysis performed. Indeed,
Trowbridge et al. study the cell-cycle status ofPtch+/ LSKs after
transplantation, while we study steady-state LSKs shortly after
SmoM2 activation. Finally, it is important to note that the gain-
of-function of a pathway effector (SmoM2) may well engender
a different hematopoietic phenotype than the loss-of-function
of a negative regulator (Ptch) that may have effects on other
signaling pathways that could influence hematopoiesis.
Our analyses also failed to demonstrate a significant effect of
Smo deletion on T cell differentiation, as proposed previously by
several studies including one from our own laboratory, in which
Smowas deleted inearlyT cell progenitors using the Lck-cre strain
(Crompton et al., 2007; El Andaloussi et al., 2006). This discrep-
ancy could be due to the differential mode of Cre-recombinase
activation and pathway deletion. Indeed, Lck-cre is only active in
early thymocytes, and it ensures deletion in both fetal and adult
thymus, suggesting again that fetal and adult hematopoiesis
have unique and distinct Hh signaling requirements. Another
reason for the phenotypic discrepancy could be that the Lck-
cre-driven thymic effect was only partial. It is thus possible that
our current studies, aimed mainly at HSC function, were not quan-
titative enough to reveal slight alterations of early T cell differenti-
ation. It is more difficult to explain the differential effects on thymic
size and progression of T cell maturation of the Mx1-cre-mediated
Smo deletion reported by El Andaloussi et al. The timing of the
analysis could provide a potential explanation. In this study, thymi
were analyzed at weeks 4 and 16 postdeletion, while El Andaloussi
et al. analyzed mice only 1 week after the last polyI:polyC injection.
It is thus possible that the outcome of these studies was dictated
by the timing of the analysis, especially as the thymus is a tissue
with enormous regenerative capacity. Additional explanations
could also include background differences, as the mice studied
here (and by Hofmann et al., 2009 [this issue of Cell Stem Cell])
are C57Bl/6 SmoF/F, while El Andaloussi et al. utilized 129X1/SvJ
SmoF/null animals. It is thus possible that the effects on T cell devel-
opment were influenced by the genetic background of the
analyzed mice. Future studies that directly compare T cell devel-
opment in the different Hh-deficient strains are necessary to
address the extent of Hh function in T cell development.
Is there any role for Hh in hematopoiesis? The strongest
evidence supporting a pivotal role of Hh signaling in hematopoi-556 Cell Stem Cell 4, 548–558, June 5, 2009 ª2009 Elsevier Inc.esis came from the study of zebrafish embryo Hh mutants (Ger-
ing and Patient, 2005). As zebrafish hematopoiesis shares
striking similarities to the mammalian fetal blood development,
it is possible that the Hh pathway, as previously suggested, plays
a more prominent role during fetal blood development. More-
over, it is possible that Hh function is masked by the synergistic
function of other signaling pathways. Indeed, pathways such as
Notch and Wnt, which have been previously shown to be
capable of interacting with Hh (Hallahan et al., 2004; Mak
et al., 2006; Yang and Niswander, 1995; Yokota et al., 2004),
could collaborate with each other to ensure self-renewal and
specify differentiation (Duncan et al., 2005). In this report, we
showed that deletion of both RBPJ and Smo did not affect
HSC function, suggesting Notch and Hh signaling do not play
synergistic roles. However, we cannot exclude potential redun-
dancy with other signaling cues.
Two recent reports (Dierks et al., 2008; Zhao et al., 2009) have
identified Smo as a drug target for the targeting of BCR-ABL+
human leukemic stem cells, introducing the notion that the Hh
pathway could be important for malignant hematopoiesis and
the maintenance of leukemia. In the lightof theseseminal findings,
our results are of further importance as they prove that pharmaco-
logical targeting of Hh in leukemia is feasible as physiological HSC
function and progression of hematopoiesis remains unaffected.
They also suggest that not all blood malignancies can be treated
using similar therapeutic protocols, as the progression of T-ALL is
not affected by the silencing of Hh function.
EXPERIMENTAL PROCEDURES
Animals
SmoF/F mice (Long et al., 2001) were a gift of Dr. A. McMahon (Harvard Univer-
sity, Boston). Genotyping of SmoF/F (Long et al., 2001; Zhang et al., 2001) and
RBPJF/F mice (Han et al., 2002; Tanigaki et al., 2004) was performed as previ-
ously reported. SmoF/FMx1-Cre animals were injected with 20 mg polyI:polyC
per gram of body weight for a total of three injections. The injections were initi-
ated 14 days after birth and done every 2 days. Animals were analyzed
4–6 weeks after the last injection unless indicated otherwise. All animal exper-
iments were done in accordance to the guidelines of the NYU School of
Medicine. Gli1lacZ mice were a gift of Dr. A. Joyner (Memorial Sloan Kettering
Cancer Center, New York). ROSA26SmoM2 mice (Jeong et al., 2004) were
purchased from Jackson Laboratory. For 5-FU experiments, 150 mg of 5-FU
per gram of body weight were intraperitoneally injected every week.
Antibodies and FACS Analysis
Antibody staining and FACS analysis were performed as previously described
(Aifantis et al., 1999). All antibodies were purchased from BD Pharmingen or
e-Bioscience. We used the following antibodies: c-kit (2B8), Sca-1 (D7),
Mac-1 (M1/70), Gr-1 (RB6-8C5), NK1.1 (PK136), TER-119, CD3 (145-2C11),
CD19 (1D3), IL7Ra (A7R34), CD34 (RAM34), FcgII/III (2.4G2), Flk-2/Flt-3
(A2F10.1), CD4 (RM4-5), CD4 (H129.19), CD8 (53-6.7), CD25 (PC61), CD44
(IM7), CD45.1 (A20), CD45.2 (104), CD150 (9D1), CD48 (HM481), Ki67, Annex-
inV, and 7-AAD. Bone marrow lineage antibody cocktail includes Mac-1, Gr-1,
NK1.1, TER-119, CD3, and CD19. For Ki67 and DAPI staining, briefly, the cells
were first treated with Fix and Perm reagents according to the manufacturer’s
instruction (Invitrogen), stained with Ki67 for 20 min at room temperature, and
then washed and resuspended in PBS with 5 mg/ml RNaseA and 2 mg/ml DAPI.
RT-PCR
Total RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN), and cDNA
was synthesized using the SuperScript First-Strand Kit (Invitrogen). Quantita-
tive PCR was performed using iQ SYBR Green Supermix and an iCycler
(Bio-Rad) using the primer sequences (Tm = 60C used for all primers)
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Hedgehog in Adult HSC Functionprovided in Table S1. T-ALL patient samples were provided by collaborating
institutions in the United States (St. Jude Children’s Research Hospital,
Memphis, TN) and Canada (Hospital for Sick Children, Toronto, Canada)
(Thompson et al., 2007).
Methylcellulose Assay
LSKcellswere flowpurified frompolyI:polyC-injectedmice.LSKcellswereplated
in duplicate (500 LSK/35mm dish) into cytokine-supplemented methylcellulose
medium (MethoCult 3434, Stem Cell Technologies), and the number and
morphologyofcolonieswerescored7days later. Forsecondary plating,cell colo-
nies were pooled from the first plating, and 4000 cells were plated in duplicate.
Bone Marrow Transplantation
Bone marrow cells (53 105) (Ly5.2+) or 500 LSKs (Ly5.2+) were transplanted by
retro-orbital i.v. injections into lethally irradiated (960 cGy) BL6SJL (Ly5.1+)
recipient mice in competition with 5 3 105 B6SJL (Ly5.1+) bone marrow cells.
Peripheral blood of recipient mice was collected at 4, 8, and 12 weeks after
transplant. For secondary transplants, recipient mice were sacrificed 16
weeks after primary transplant. Ly5.2+ bone marrow cells were flow purified,
and 5 3 105 cells were transplanted by retro-orbital i.v. injections into lethally
irradiated (960 cGy) BL6SJL (Ly5.1+) recipient mice in competition with 53 105
B6SJL (Ly5.1+) bone marrow cells.
Microarray Analysis
A group of four mice was pooled for each condition. Microarray analysis was
performed as previously described (Thompson et al., 2008). Briefly, freshly
isolated cells were sorted by surface marker expression, and total RNA was
extracted using the RNeasy kit (QIAGEN). In order to generate sufficient
sample quantities for oligonucleotide gene chip hybridization experiments,
we used the GeneChip Two-Cycle cDNA Synthesis Kit (Affymetrix, San
Jose, CA) for cRNA amplification and labeling. The amplified cRNA was
labeled and hybridized to the MOE430 Plus 2 oligonucleotide arrays (Affyme-
trix). The Affymetrix gene expression profiling data were normalized using the
previously published Robust Multi-Array Average (RMA) algorithm using the
GeneSpring 7 software (Agilent, Palo Alto, CA). The gene expression intensity
presentation was generated with MeV software (http://www.tm4.org).
Retroviral Infection of Lineage-Negative Bone Marrow Cells
Bone marrow cells were enriched for lineage-negative cells using EasySep kit
(StemCell Technology) and were cultured in OPTI-MEM supplemented with
10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 ng/
ml SCF and Flt3l, and 10 ng/ml IL6 and IL7. For retroviral production, phoenix
cells were transfected with pMigNotch-IC by calcium phosphate method.
Virus supernatant was collected 48 hr posttransfection and used directly for
spin infection of lineage-depleted bone marrow cells at 2500 rpm for 90 min.
Forty-eight hours after infection, 1 3 105 lineage-negative GFP-positive cells
were i.v. injected into one lethally irradiated (960 cGy) C57BL/6J host mouse.
Statistical Analysis
The means of each data set were analyzed by using the Student’s t test with
a two-tailed distribution and assuming equal sample variance.
ACCESSION NUMBERS
Microarray data were deposited at the Gene Expression Omnibus (GEO) data-
base under the accession number GSE15194.
SUPPLEMENTAL DATA
Supplemental Data include one table and six figures and can be found with
this article online at http://www.cell.com/cell-stem-cell/supplemental/S1934-
5909(09)00151-9.
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